Buckingham Strategic Wealth’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | $267K | Sell |
3,896
-1,792
| -32% | -$120K | ﹤0.01% | 628 |
|
|
2024
Q1 | $417K | Sell |
5,688
-518
| -8% | -$39.8K | ﹤0.01% | 510 |
|
|
2023
Q4 | $503K | Buy |
6,206
+358
| +6% | +$27.9K | 0.01% | 442 |
|
|
2023
Q3 | $438K | Sell |
5,848
-265
| -4% | -$20.4K | 0.01% | 449 |
|
|
2023
Q2 | $471K | Buy |
6,113
+647
| +12% | +$51.6K | 0.01% | 434 |
|
|
2023
Q1 | $469K | Hold |
5,466
| – | – | 0.01% | 392 |
|
|
2022
Q4 | $469K | Buy |
5,466
+378
| +7% | +$29.9K | 0.01% | 394 |
|
|
2022
Q3 | $314K | Sell |
5,088
-275
| -5% | -$17.3K | 0.01% | 462 |
|
|
2022
Q2 | $331K | Buy |
5,363
+964
| +22% | +$59.7K | 0.01% | 449 |
|
|
2022
Q1 | $262K | Sell |
4,399
-447
| -9% | -$28.6K | 0.01% | 501 |
|
|
2021
Q4 | $352K | Sell |
4,846
-1,795
| -27% | -$124K | 0.01% | 438 |
|
|
2021
Q3 | $464K | Sell |
6,641
-228
| -3% | -$16K | 0.01% | 371 |
|
|
2021
Q2 | $473K | Buy |
6,869
+686
| +11% | +$45.8K | 0.01% | 376 |
|
|
2021
Q1 | $400K | Sell |
6,183
-546
| -8% | -$35.2K | 0.02% | 376 |
|
|
2020
Q4 | $392K | Buy |
6,729
+383
| +6% | +$23.1K | 0.02% | 363 |
|
|
2020
Q3 | $401K | Buy |
6,346
+521
| +9% | +$36.1K | 0.03% | 302 |
|
|
2020
Q2 | $448K | Sell |
5,825
-86
| -1% | -$6.59K | 0.04% | 235 |
|
|
2020
Q1 | $442K | Buy |
5,911
+131
| +2% | +$9.05K | 0.04% | 269 |
|
|
2019
Q4 | $376K | Buy |
5,780
+1,123
| +24% | +$73.1K | 0.04% | 301 |
|
|
2019
Q3 | $295K | Sell |
4,657
-40,773
| -90% | -$2.67M | 0.03% | 328 |
|
|
2019
Q2 | $3.07M | Buy |
45,430
+1,053
| +2% | +$69.3K | 0.33% | 68 |
|
|
2019
Q1 | $2.88M | Buy |
44,377
+40,479
| +1,038% | +$2.69M | 0.36% | 66 |
|
|
2018
Q4 | $244K | Sell |
3,898
-2,025
| -34% | -$142K | 0.04% | 297 |
|
|
2018
Q3 | $457K | Buy |
5,923
+45
| +0.8% | +$3.4K | 0.07% | 202 |
|
|
2018
Q2 | $416K | Sell |
5,878
-614
| -9% | -$43.4K | 0.07% | 208 |
|
|
2018
Q1 | $489K | Buy |
6,492
+1,693
| +35% | +$135K | 0.1% | 168 |
|
|
2017
Q4 | $344K | Buy |
4,799
+427
| +10% | +$32.4K | 0.07% | 216 |
|
|
2017
Q3 | $354K | Sell |
4,372
-191
| -4% | -$14.6K | 0.08% | 197 |
|
|
2017
Q2 | $323K | Sell |
4,563
-2,010
| -31% | -$134K | 0.08% | 209 |
|
|
2017
Q1 | $446K | Buy |
6,573
+483
| +8% | +$34K | 0.13% | 150 |
|
|
2016
Q4 | $436K | Sell |
6,090
-767
| -11% | -$57K | 0.14% | 129 |
|
|
2016
Q3 | $543K | Sell |
6,857
-374
| -5% | -$30.4K | 0.18% | 106 |
|
|
2016
Q2 | $603K | Sell |
7,231
-3,208
| -31% | -$285K | 0.21% | 103 |
|
|
2016
Q1 | $959K | Buy |
10,439
+3,690
| +55% | +$333K | 0.32% | 64 |
|
|
2015
Q4 | $683K | Buy |
6,749
+624
| +10% | +$64.9K | 0.23% | 79 |
|
|
2015
Q3 | $601K | Buy |
6,125
+1,342
| +28% | +$149K | 0.21% | 88 |
|
|
2015
Q2 | $560K | Sell |
4,783
-707
| -13% | -$77.3K | 0.18% | 99 |
|
|
2015
Q1 | $539K | Buy |
5,490
+458
| +9% | +$46.5K | 0.2% | 92 |
|
|
2014
Q4 | $474K | Buy |
5,032
+1,376
| +38% | +$142K | 0.18% | 95 |
|
|
2014
Q3 | $389K | Buy |
3,656
+370
| +11% | +$36.2K | 0.16% | 102 |
|
|
2014
Q2 | $272K | Sell |
3,286
-885
| -21% | -$68.9K | 0.12% | 123 |
|
|
2014
Q1 | $296K | Sell |
4,171
-84
| -2% | -$6.59K | 0.14% | 104 |
|
|
2013
Q4 | $320K | Buy |
4,255
+333
| +8% | +$23.2K | 0.15% | 100 |
|
|
2013
Q3 | $247K | Sell |
3,922
-47
| -1% | -$2.81K | 0.13% | 106 |
|
|
2013
Q2 | $203K | Buy |
+3,969
| New | +$207K | 0.11% | 119 |
|
Other funds holding GILD
Buckingham Strategic Wealth's GILD Position: Q2 2024 in Review
Buckingham Strategic Wealth reduced its Gilead Sciences (GILD) stake by 32% in Q2 2024, selling an estimated $120K and leaving 3,896 shares worth $267K. The position accounts for ﹤0.01% of the portfolio, ranked #628.
Buckingham Strategic Wealth first reported a position in GILD in Q2 2013 and has held it in 45 quarters since. The position peaked at $3.07M in Q2 2019. 1,678 funds tracked by Wall St. Rank hold GILD as of Q2 2024.
- Buckingham Strategic Wealth held 3,896 shares of Gilead Sciences worth $267K as of Q2 2024.
- Buckingham Strategic Wealth sold 1,792 Gilead Sciences shares in Q2 2024, an estimated $120K.
- Gilead Sciences made up ﹤0.01% of Buckingham Strategic Wealth's portfolio in Q2 2024, its #628 holding.
- Buckingham Strategic Wealth first reported a position in Gilead Sciences in Q2 2013 and has held it in 45 quarters since.
- Buckingham Strategic Wealth's Gilead Sciences position peaked at $3.07M in Q2 2019.
- 1,678 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2024.
Based on Buckingham Strategic Wealth's 13F filing for Q2 2024, filed 12 Aug 2024.